Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, and Yourgene Health segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The company was incorporated in 2006 and is based in Eastleigh, the United Kingdom.
| 0.754 | |
| 0.754 | |
| - | |
| 0.754 | |
| 0.754 | |
| 0.5-1.25 | |
| 53 252 K | |
| 70 626 K | |
| 18 562 K | |
| -1.859 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
PARIS & EASTLEIGH, England, January 30, 2023--(BUSINESS WIRE)--Regulatory News: Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Hi...
Full year revenue and EBITDA in line with guidance Remain focused on post-COVID-19 growth strategy to become a leading global clinical diagnostics company in infectious diseases PARIS & EASTLEIGH, E...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
